CMSC Practical Guidelines for the Selection of Disease-Modifying Therapies in Multiple Sclerosis
Type:
Enduring Material
Credit Hours:
7
Session Description:
This guideline was developed by a group of multiple sclerosis (MS) specialists, convened by the Consortium of Multiple Sclerosis Centers (CMSC), to serve as an educational guide and concise summary of available data and professional recommendations on the selection of disease-modifying therapy (DMT) for MS. The group met in Chicago, IL, in 2018 at a conference independently sponsored by the CMSC to discuss and debate current concepts on DMT use.
DMT CONSENSUS COMMITTEE PROGRAM CHAIRS
Corey C. Ford, MD, PhD
Professor of Neurology; Senior Associate Dean for Research
Director, MS Specialty Clinic
University of New Mexico Health Sciences Center,
Albuquerque, NM
Sarah A. Morrow, MD, MS, FRCPC
Associate Professor, Clinical Neurological Sciences
Western University, London Multiple Sclerosis Clinic
London, Ontario, Canada
FACULTY CONSULTANTS
Guy Buckle, MD, MPH
Professor of Neurology; Director, Neuroimaging Research
MS Institute at Shepherd Center, Atlanta, GA
Patricia K. Coyle, MD
Professor of Neurology; Director, MS Comprehensive Care Center
Stony Brook University Medical Center, Stony Brook, NY
Jennifer Graves, MD, PhD
Associate Professor of Neurosciences; Director,
UCSD Neuro-immunology Research Program
University of California San Diego, San Diego, CA
June Halper, MSN, APN-C, MSN
Chief Executive Officer
Consortium of Multiple Sclerosis Center
Colleen Harris, MN, NP, MSCN
Nurse Coordinator/Nurse Practitioner,
University of Calgary MS Clinic
Foothills Hospital, Calgary, Alberta, Canada
Sharon Lynch, MD
Professor of Neurology; Division Chief,
MS and Neuroimmunology
University of Kansas Medical Center MS Center, Kansas City, KS
Lori Mayer, DNP, MSN, RN, MSCN
Director, Medical Research Services
MS Clinic of Central Texas, Round Rock, TX
Robert Naismith, MD
Associate Professor of Neurology; Director,
John L. Trotter MS Clinic
Director, Multiple Sclerosis Clinical Trials Program
Washington University School of Medicine, St Louis, MO
Eluen Ann Yeh, MD, MS
Associate Professor, Department of Pediatrics,
University of Toronto
Staff Neurologist, Hospital for Sick Children
Toronto, Ontario, Canada
Jointly provided by the Consortium of Multiple Sclerosis Centers and Delaware Media Group.
DMT CONSENSUS COMMITTEE PROGRAM CHAIRS
Corey C. Ford, MD, PhD
Professor of Neurology; Senior Associate Dean for Research
Director, MS Specialty Clinic
University of New Mexico Health Sciences Center,
Albuquerque, NM
Sarah A. Morrow, MD, MS, FRCPC
Associate Professor, Clinical Neurological Sciences
Western University, London Multiple Sclerosis Clinic
London, Ontario, Canada
FACULTY CONSULTANTS
Guy Buckle, MD, MPH
Professor of Neurology; Director, Neuroimaging Research
MS Institute at Shepherd Center, Atlanta, GA
Patricia K. Coyle, MD
Professor of Neurology; Director, MS Comprehensive Care Center
Stony Brook University Medical Center, Stony Brook, NY
Jennifer Graves, MD, PhD
Associate Professor of Neurosciences; Director,
UCSD Neuro-immunology Research Program
University of California San Diego, San Diego, CA
June Halper, MSN, APN-C, MSN
Chief Executive Officer
Consortium of Multiple Sclerosis Center
Colleen Harris, MN, NP, MSCN
Nurse Coordinator/Nurse Practitioner,
University of Calgary MS Clinic
Foothills Hospital, Calgary, Alberta, Canada
Sharon Lynch, MD
Professor of Neurology; Division Chief,
MS and Neuroimmunology
University of Kansas Medical Center MS Center, Kansas City, KS
Lori Mayer, DNP, MSN, RN, MSCN
Director, Medical Research Services
MS Clinic of Central Texas, Round Rock, TX
Robert Naismith, MD
Associate Professor of Neurology; Director,
John L. Trotter MS Clinic
Director, Multiple Sclerosis Clinical Trials Program
Washington University School of Medicine, St Louis, MO
Eluen Ann Yeh, MD, MS
Associate Professor, Department of Pediatrics,
University of Toronto
Staff Neurologist, Hospital for Sick Children
Toronto, Ontario, Canada
Jointly provided by the Consortium of Multiple Sclerosis Centers and Delaware Media Group.
Learning Objectives:
Target Audience:
Neurologists, primary care physicians, physician assistants (PAs), nursing professionals, pharmacists, and other members of the care team who manage patients with MS.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Delaware Media Group. The CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurse Credentialing Center (ANCC) to provide continuing medical education for the healthcare team.
The CMSC designates this enduring material for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The CMSC designates this enduring material for a maximum of 7.0 Continuing Nursing Education Credits (7.0 of these credits are in the area of pharmacology).
The Consortium of Multiple Sclerosis Centers (CMSC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education and will award 7.0 contact hours (0.7 CEUs) to pharmacists who (1) complete the activity, (2) submit a passing posttest, and (3) complete the evaluation form. The Universal Activity Number (UAN) for this activity is JA4008165-9999-19-001-H01-P. This is a knowledge-based activity.
Upon successful completion of the activity, your CE credits will be submitted electronically to the NABP CPE Monitor service. For information about CPE Monitor, visit https://nabp.pharmacy/cpe-monitor-service/
Paper certificates are not valid for pharmacy credit.
Certificate of Completion
A Certificate of Completion may be given upon completion of course requirements enabling you to register your credit with the appropriate licensing boards or associations. You may apply for other accreditations using the procedure established by the specific organization.
Laurie Scudder, DNP, NP, has served as Nurse Planner and Reviewer for this activity. She has no relevant financial relationships to disclose.
Method of Participation:
Release Date: February 28, 2019
Valid for Credit Through: February 29, 2020
There is no fee to participate in this activity.
To receive credit, participants must:
Disclosure of Financial Relationships
It is the policy of CMSC and Delaware Media Group to ensure balance, independence, objectivity, and scientific rigor in all educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed any relevant financial relationships they or their spouse/life partner have within the previous 12 months with manufacturers of any commercial products/ devices and/or providers of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. All presentations were reviewed by an independent clinician with no relevant financial relationships for the purpose of resolution of any identified conflict of interest and a determination of evidence-base and fair balance.
Faculty Disclosures
The faculty reported the following financial relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
Faculty Chairs
Corey C. Ford, MD, PhD, has disclosed no relevant financial relationships.
Sarah A. Morrow, MD, MS, FRCPC, has received consulting fees from Biogen, EMD Serono, Novartis, Roche, and Sanofi Genzyme.
Faculty
Guy Buckle, MD, MPH, has received consulting fees from EMD Serono, Biogen, Genentech, Novartis, Teva, and Genzyme. He has also served on Speakers' Bureaus for EMD Serono, Biogen, Genentech, Novartis, Teva, and Genzyme.
Patricia K. Coyle, MD, has received consulting fees from Accorda, Bayer, Biogen, Celgene, Genentech, Sanofi Genzyme, Novartis, EMD Serono, and Teva. She has performed contracted research for Actelion, Alkermes, Biogen, Genentech, MedDay, NINDS, and Novartis.
Jennifer Graves, MD, PhD, has received research funding from Biogen and serves on a Speaker's Bureau for Novartis.
Colleen Harris, MN, NP, MSCN, has received consulting fees from EMD Serono, Biogen, Pendopharm, Roche and Sanofi Genzyme.
Sharon Lynch, MD, has received research support from Actelion, Biogen, Genzyme, Mallinckrodt, MedDay, Novartis, PCORI, Roche, and Sanofi.
Lori Mayer, DNP, MSN, RN, MSCN, has received consulting fees from Biogen, Genentech, Sanofi Genzyme, Novartis, and EMD Serono. She has served on Speakers' Bureaus for Biogen, Genentech, Sanofi Genzyme, Novartis, and EMD Serono.
Robert Naismith, MD, has received consulting fees from Alkermes, Biogen, EMD Serono, and Novartis and serves on the Speaker's Bureaus for Genentech, Genzyme, and Novartis.
Eluen Ann Yeh, MD, MA, has received research funding from Biogen and Teva Pharmaceuticals.
Reviewers/Planners
June Halper, MSN, APN-C, MSCN, FAAN, served as Planner for this activity and has disclosed no relevant financial relationships.
Laurie Scudder, DNP, NP, served as Nurse Planner for this activity and has disclosed no relevant financial relationships.
Katherine Wandersee served as Medical Writer for this activity and has disclosed no relevant financial relationships. All other planners, reviewers, editors, staff, and other members at the Consortium of Multiple Sclerosis Centers (CMSC) and Delaware Media Group who are in a position to control content have declared no relevant financial relationships.
Acknowledgement:
The development of this guideline was funded solely by the Consortium of Multiple Sclerosis Centers. The supplement was supported by educational grants from Avanir Pharmaceuticals, Biogen, EMD Serono, and Sanofi Genzyme.
Disclosure of Unlabeled Use
CMSC and Delaware Media Group require faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/ or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are CMSC Practical Guidelines for the Selection of Disease-Modifying Therapies in Multiple Sclerosis CMSC DMT Guideline Writing Group CMSC Practical Guidelines 3 preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians
without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer/mobile device with an internet connection/browser sufficient for viewing the educational content.
- Identify frameworks for therapeutic decision making for disease modifying treatment of different forms of multiple sclerosis.
- Determine rationale for switching therapies for patients with MS to optimize disease management based on individual efficacy, safety, and tolerability needs.
- Discuss recent changes and ongoing challendes associated with MS treatment inclusing decisions about starting, stopping, and escalating therapy.
Target Audience:
Neurologists, primary care physicians, physician assistants (PAs), nursing professionals, pharmacists, and other members of the care team who manage patients with MS.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Delaware Media Group. The CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurse Credentialing Center (ANCC) to provide continuing medical education for the healthcare team.
The CMSC designates this enduring material for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The CMSC designates this enduring material for a maximum of 7.0 Continuing Nursing Education Credits (7.0 of these credits are in the area of pharmacology).
The Consortium of Multiple Sclerosis Centers (CMSC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education and will award 7.0 contact hours (0.7 CEUs) to pharmacists who (1) complete the activity, (2) submit a passing posttest, and (3) complete the evaluation form. The Universal Activity Number (UAN) for this activity is JA4008165-9999-19-001-H01-P. This is a knowledge-based activity.
Upon successful completion of the activity, your CE credits will be submitted electronically to the NABP CPE Monitor service. For information about CPE Monitor, visit https://nabp.pharmacy/cpe-monitor-service/
Paper certificates are not valid for pharmacy credit.
Certificate of Completion
A Certificate of Completion may be given upon completion of course requirements enabling you to register your credit with the appropriate licensing boards or associations. You may apply for other accreditations using the procedure established by the specific organization.
Laurie Scudder, DNP, NP, has served as Nurse Planner and Reviewer for this activity. She has no relevant financial relationships to disclose.
Method of Participation:
Release Date: February 28, 2019
Valid for Credit Through: February 29, 2020
There is no fee to participate in this activity.
To receive credit, participants must:
- Read the activity front matter,
- complete the educational activity online, and
- complete the post-test and activity evaluation. To receive credit, participants must receive a minimum score of 70% on the post-test.
Disclosure of Financial Relationships
It is the policy of CMSC and Delaware Media Group to ensure balance, independence, objectivity, and scientific rigor in all educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed any relevant financial relationships they or their spouse/life partner have within the previous 12 months with manufacturers of any commercial products/ devices and/or providers of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. All presentations were reviewed by an independent clinician with no relevant financial relationships for the purpose of resolution of any identified conflict of interest and a determination of evidence-base and fair balance.
Faculty Disclosures
The faculty reported the following financial relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
Faculty Chairs
Corey C. Ford, MD, PhD, has disclosed no relevant financial relationships.
Sarah A. Morrow, MD, MS, FRCPC, has received consulting fees from Biogen, EMD Serono, Novartis, Roche, and Sanofi Genzyme.
Faculty
Guy Buckle, MD, MPH, has received consulting fees from EMD Serono, Biogen, Genentech, Novartis, Teva, and Genzyme. He has also served on Speakers' Bureaus for EMD Serono, Biogen, Genentech, Novartis, Teva, and Genzyme.
Patricia K. Coyle, MD, has received consulting fees from Accorda, Bayer, Biogen, Celgene, Genentech, Sanofi Genzyme, Novartis, EMD Serono, and Teva. She has performed contracted research for Actelion, Alkermes, Biogen, Genentech, MedDay, NINDS, and Novartis.
Jennifer Graves, MD, PhD, has received research funding from Biogen and serves on a Speaker's Bureau for Novartis.
Colleen Harris, MN, NP, MSCN, has received consulting fees from EMD Serono, Biogen, Pendopharm, Roche and Sanofi Genzyme.
Sharon Lynch, MD, has received research support from Actelion, Biogen, Genzyme, Mallinckrodt, MedDay, Novartis, PCORI, Roche, and Sanofi.
Lori Mayer, DNP, MSN, RN, MSCN, has received consulting fees from Biogen, Genentech, Sanofi Genzyme, Novartis, and EMD Serono. She has served on Speakers' Bureaus for Biogen, Genentech, Sanofi Genzyme, Novartis, and EMD Serono.
Robert Naismith, MD, has received consulting fees from Alkermes, Biogen, EMD Serono, and Novartis and serves on the Speaker's Bureaus for Genentech, Genzyme, and Novartis.
Eluen Ann Yeh, MD, MA, has received research funding from Biogen and Teva Pharmaceuticals.
Reviewers/Planners
June Halper, MSN, APN-C, MSCN, FAAN, served as Planner for this activity and has disclosed no relevant financial relationships.
Laurie Scudder, DNP, NP, served as Nurse Planner for this activity and has disclosed no relevant financial relationships.
Katherine Wandersee served as Medical Writer for this activity and has disclosed no relevant financial relationships. All other planners, reviewers, editors, staff, and other members at the Consortium of Multiple Sclerosis Centers (CMSC) and Delaware Media Group who are in a position to control content have declared no relevant financial relationships.
Acknowledgement:
The development of this guideline was funded solely by the Consortium of Multiple Sclerosis Centers. The supplement was supported by educational grants from Avanir Pharmaceuticals, Biogen, EMD Serono, and Sanofi Genzyme.
Disclosure of Unlabeled Use
CMSC and Delaware Media Group require faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/ or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are CMSC Practical Guidelines for the Selection of Disease-Modifying Therapies in Multiple Sclerosis CMSC DMT Guideline Writing Group CMSC Practical Guidelines 3 preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians
without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer/mobile device with an internet connection/browser sufficient for viewing the educational content.
Credit Types
ACPE: 7.00
CME: 7.00
Letter of Completion: 7.00
NCPD: 7.00
NCPD - Pharmacology: 7.00
